Retatrutide Dosing: How It Was Titrated in Trials (and Why There's No Approved Dose)
Retatrutide has no FDA-approved dose. Here is what the phase 2 trial actually used: once-weekly escalation to 1, 4, 8, or 12 mg, titrated monthly, and what each dose produced, plus why anything sold online as retatrutide is unapproved and unsafe to self-dose.
By WeighedHealth Editorial
6 min readUpdated
- 0
- FDA-approved retatrutide doses (it is investigational, not prescribable)
- 0, 4, 8, 12 mg
- Once-weekly maintenance doses tested in the phase 2 trial
- 0.0%
- Mean weight change at 48 weeks on the highest (12 mg) dose
- ~0.0 bpm
- Peak average heart-rate increase at 12 mg, around week 24
Jump to section
The short version
Retatrutide is an investigational triple-hormone-receptor agonist. It is not FDA-approved for any use, so there is no official, prescribable dose and no dosing chart a clinician can legally follow. The only human dosing data comes from clinical trials. In the phase 2 obesity trial, adults were escalated to a once-weekly maintenance dose of 1, 4, 8, or 12 mg, stepped up gradually over the first 12 weeks, then held steady through week 48 [1].
Higher trial doses produced more weight loss but also larger increases in heart rate. Because retatrutide is still being studied and has no approved formulation, any product sold online as "retatrutide" is unapproved, unregulated, and cannot be assumed to contain what the label claims. This page explains the trial doses as evidence, not as instructions for self-use.
There is no approved retatrutide dose
Start here because it changes how you should read everything else: as of 2026, retatrutide has completed phase 2 and is in phase 3 trials, but it has not received FDA approval. No approved strength, no approved starting dose, no approved titration schedule exists. A doctor cannot write a legitimate prescription for it outside of a clinical trial.
That matters for a practical reason. Approved GLP-1 medicines come as manufactured pens with a fixed, tested amount of drug per dose and a labeled titration path. Retatrutide has none of that outside the trial setting. The numbers below describe what researchers gave participants under medical supervision with pharmaceutical-grade drug. They are not a template for dosing a vial bought online.
The doses tested in the phase 2 trial
The phase 2 trial enrolled 338 adults with obesity, or overweight with a weight-related condition, and randomly assigned them to placebo or one of four maintenance doses of once-weekly subcutaneous retatrutide: 1 mg, 4 mg, 8 mg, or 12 mg [1]. Some groups were split by starting dose to test whether beginning at 2 mg versus 4 mg changed how well the drug was tolerated.
So the "dose" of retatrutide in the study was really a target maintenance dose that participants worked up to over time, not a dose they started at. The 12 mg arm, for example, did not begin at 12 mg.
How the trial titrated: slow monthly step-ups
Every participant started low and escalated over roughly the first 12 weeks before holding the assigned maintenance dose for the remaining 36 weeks [1]. The step-ups happened in stages, about every four weeks, so the body had time to adjust between increases. The 12 mg group, for instance, started at 2 mg and moved up in steps to reach 12 mg by around week 12.
The reason for the slow climb is the same reason approved GLP-1 drugs titrate: the gastrointestinal side effects (nausea, vomiting, diarrhea, constipation) are worst when the dose jumps, and they ease when the increase is gradual. The trial found GI side effects were mostly mild to moderate and were partly reduced by starting at 2 mg instead of 4 mg [1]. Jumping straight to a high dose is exactly what the escalation schedule was designed to avoid.
What each dose produced at 48 weeks
Weight loss rose with dose. At week 48, least-squares mean weight change from baseline was about -8.7% at 1 mg, -17.1% at 4 mg, -22.8% at 8 mg, and -24.2% at 12 mg, versus -2.1% for placebo [1]. The share of people losing at least 15% of body weight also climbed with dose: roughly 60% at 4 mg, 75% at 8 mg, and 83% at 12 mg, compared with 2% on placebo [1].
Two things are worth reading carefully. First, weight was still trending down at week 48 in the higher-dose groups, meaning the full effect may not have been reached. Second, these are averages under controlled conditions; individual results varied, and phase 2 was not designed to establish a final approved dose. Phase 3 exists precisely to settle dose, long-term safety, and durability.
The heart-rate signal and why dose is not just about weight
Bigger doses did not only mean more weight loss. Retatrutide produced dose-dependent increases in heart rate that peaked around week 24 and then declined through week 48 [1]. Reported average increases were in the range of a few beats per minute at lower doses up to roughly 6 to 7 bpm at the highest dose. Blood pressure changes and other safety signals were also tracked.
This is the core reason self-selecting a high dose is a bad idea. A resting heart-rate rise is a cardiovascular effect that needs monitoring, and it is one of the specific questions phase 3 trials are powered to answer. In the trial, participants having this happen were under clinician oversight with scheduled follow-up. Someone dosing at home from an online vial has none of that safety net.
How approved GLP-1 drugs titrate, for contrast
The escalation logic in the retatrutide trial mirrors how approved GLP-1 medicines are dosed. Semaglutide for weight management (Wegovy) starts at 0.25 mg once weekly for four weeks, then steps up through 0.5, 1, and 1.7 mg at roughly four-week intervals to a 2.4 mg maintenance dose [2]. Tirzepatide (Zepbound) starts at 2.5 mg once weekly for four weeks, then increases in 2.5 mg steps to a maintenance dose of 5, 10, or 15 mg [3].
The shared principle is start low, go slow, stop stepping up once you reach an effective and tolerated dose. The difference is that Wegovy and Zepbound come in labeled pens with a validated schedule your prescriber follows. Retatrutide's trial schedule is not a substitute for an approved label, because the drug, the strength, and the source are all unregulated outside the trial.
Why "retatrutide" sold online is unapproved and unsafe
Because retatrutide has no approval, it also has no approved manufacturer selling it to the public. Products marketed online as retatrutide, often labeled "for research use only" or sold as a peptide, are not FDA-approved medicines and are not made under the quality controls that apply to approved drugs. There is no guarantee of identity, purity, strength, or sterility, and the actual amount of drug in a vial can differ from what the label says.
That uncertainty compounds the dosing problem. Even if you copied a trial dose exactly, you cannot know you are receiving that dose, and you would be self-administering an injectable with a known cardiovascular signal and no clinician monitoring. The FDA has repeatedly warned about unapproved and compounded GLP-class products for these reasons [4]. The honest answer to "what dose should I take" is that there is no safe way to self-dose an unapproved injectable.
Bottom line
Retatrutide's trial doses (1, 4, 8, and 12 mg once weekly, reached by slow monthly escalation) are useful for understanding how the drug performed, and they show a clear dose-response for weight loss alongside a dose-dependent heart-rate rise [1]. They are not a prescribing guide. Until phase 3 finishes and, if approved, an FDA label defines a real dose, there is no legitimate retatrutide dosing for use outside a trial.
If you want the effect retatrutide is chasing now, the evidence-backed, prescribable options are approved GLP-1 medicines with defined titration schedules and clinician oversight. If you are specifically interested in retatrutide, the appropriate path is asking a clinician about enrolling in a registered clinical trial, not buying a vial online.
Sources
Primary sources cited above. FDA labeling, peer-reviewed trials, and specialty-society guidelines only.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial · New England Journal of Medicine (Jastreboff AM, et al.), 2023 · PMID 37366315
- Wegovy (semaglutide) injection — Prescribing Information (Dosage and Administration) · U.S. Food and Drug Administration, 2021
- Zepbound (tirzepatide) injection — Prescribing Information (Dosage and Administration) · U.S. Food and Drug Administration, 2023
- Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss — risks of compounded and unapproved products · U.S. Food and Drug Administration, 2024
People also ask
What is the recommended dose of retatrutide?
There is no recommended or FDA-approved dose. Retatrutide is investigational and has not been approved for any use, so no clinician can legitimately prescribe a dose outside of a clinical trial. The only human dosing information comes from research studies. In the phase 2 obesity trial, participants were escalated to a once-weekly maintenance dose of 1, 4, 8, or 12 mg, reached gradually over about 12 weeks. Those are trial doses given under medical supervision with pharmaceutical-grade drug, not a dosing guide for personal use, and they should not be copied from an online vial.
What doses of retatrutide were used in the trials?
The phase 2 trial tested four once-weekly maintenance doses of subcutaneous retatrutide: 1 mg, 4 mg, 8 mg, and 12 mg, compared with placebo, in 338 adults over 48 weeks. Participants did not start at those doses. Everyone began low and stepped up over roughly the first 12 weeks before holding the assigned dose. Some groups were split to compare a 2 mg versus 4 mg starting dose to see which was better tolerated. Higher maintenance doses produced more weight loss but also larger heart-rate increases, which is one reason dose selection is still being studied in phase 3.
How is retatrutide titrated up?
In the phase 2 trial, retatrutide was titrated slowly. Participants started at a low dose, commonly 2 mg once weekly, and increased in steps roughly every four weeks over about 12 weeks until reaching their assigned maintenance dose, which they then held. The gradual climb exists to limit gastrointestinal side effects like nausea and vomiting, which are worst when the dose jumps. The trial found starting at 2 mg instead of 4 mg reduced these effects. This escalation happened under clinician oversight, and there is no approved at-home titration schedule for retatrutide.
How much weight did each retatrutide dose produce?
At week 48 in the phase 2 trial, mean weight change from baseline was about -8.7% at 1 mg, -17.1% at 4 mg, -22.8% at 8 mg, and -24.2% at 12 mg, versus -2.1% for placebo. The proportion of people losing at least 15% of body weight rose with dose, reaching roughly 83% at 12 mg. Weight was still trending downward at week 48 in the higher-dose groups. These are averages under controlled trial conditions and were not intended to define a final approved dose, which is what the ongoing phase 3 program is designed to establish.
Does retatrutide raise heart rate at higher doses?
Yes. In the phase 2 trial, retatrutide caused dose-dependent increases in resting heart rate. The increases peaked around week 24 and then declined through week 48. Reported average rises ranged from a few beats per minute at lower doses up to roughly 6 to 7 beats per minute at the highest dose. This cardiovascular effect is one of the specific safety questions phase 3 trials are designed to answer, and it is a key reason self-selecting a high dose without monitoring is unsafe. Trial participants were followed on a schedule with clinical oversight.
Is retatrutide sold online safe to dose yourself?
No. Retatrutide has no FDA approval and no approved manufacturer selling it to the public, so products marketed online, often as peptides or "research use only," are unapproved and unregulated. They are not made under the quality controls that apply to approved drugs, and the actual identity, purity, and amount of drug can differ from the label. Even copying a trial dose exactly would not guarantee you received that dose. Combined with a known heart-rate effect and no clinician monitoring, there is no safe way to self-dose an unapproved injectable like this.
How does retatrutide dosing compare to Wegovy or Zepbound?
The escalation logic is similar, but the legal status is not. Wegovy (semaglutide) starts at 0.25 mg weekly and steps up over about 16 to 20 weeks to a 2.4 mg maintenance dose. Zepbound (tirzepatide) starts at 2.5 mg weekly and increases in 2.5 mg steps to a 5, 10, or 15 mg maintenance dose. All three share the start-low, go-slow principle. The difference is that Wegovy and Zepbound are FDA-approved, come in labeled pens with tested strengths, and are prescribed with a validated schedule. Retatrutide has none of that outside a clinical trial.
Related reads
Retatrutide: the triple-agonist obesity drug and its record 24% weight loss (2026)
Retatrutide is an investigational triple-hormone-receptor agonist that produced the largest average weight loss of any obesity drug published to date — about 24% at 48 weeks in its phase 2 trial. Here's what the evidence shows, how it differs from Wegovy and Zepbound, and its actual status.
Peptides for weight loss: what actually works, what's unproven, what's illegal
The only weight-loss peptides with FDA approval and large human trials are the GLP-1 drugs — semaglutide (~15% mean loss in STEP-1) and tirzepatide (~21% in SURMOUNT-1). Most products marketed online as 'weight-loss peptides' (BPC-157, ipamorelin, 'research-grade' retatrutide) have no human efficacy trials, no FDA oversight, and no sterility assurance.
Wegovy weight loss timeline: week-by-week expectations (2026)
Wegovy doesn't drop the scale immediately. Most patients lose 1-2 pounds in weeks 1-4, hit a 5% loss around month 4, reach 10% by month 8, and approach 15% by week 68. Here's what to actually expect, what's normal during titration, and when to call your prescriber if results lag.